Fertility preservation has recently gained a worldwide interest among fertility specialists, oncologists, and all healthcare providers. Thus, the protection against iatrogenic infertility caused by chemotherapy assumes a high priority. Specifically, the issue of endocrine prevention of gonadotoxicity is still a controversial subject.
INTRODUCTION
The increase in cancer incidence in the young age, and the significant increase in the long-term survival have brought about a ubiquitous interest in the endeavor to preserve fertility in young patients exposed to gonadotoxic chemotherapy. Indeed, malignancy is estimated to occur in about 2% of women under the age of 40 in the United States [1 & ,2,3,4 && ,5]. Among the various methods of fertility preservation despite gonadotoxic chemotherapy, endocrine suppression of ovarian function has been one of the most debatable and equivocal issues among reproductive endocrinologists, oncologists, and fertility preservation professionals [ 12, 13] . Endocrine ovarian suppression with gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy is an attractive option to preserve gonadal function and fertility with the advantage of causing no delay in the initiation of anticancer therapies and the wide availability of such compounds [5,10 && ]. Nevertheless, despite extensive research efforts in this field consisting of six randomized controlled trials (RCTs) and 13 metaanalyses, this issue is still equivocal [5, 10 have passed since the publications of these societies' clinical practice guidelines on fertility preservation in cancer patients, and new pertinent data in this field have become available [1 & ,4 && ,5,10 && ]. Although endocrine ovarian suppression with GnRHa during chemotherapy is still considered an experimental method at this time, recent data suggest both safety and efficacy for the use of GnRHa in women receiving (neo)adjuvant chemotherapy for breast cancer [ ].
REVIEW
The GnRHas induce an initial increase in gonadotropin secretion because of their agonistic nature, the 'flare-up' effect. Within several days ( According to accepted dogma, the primordial and primary follicles are considered to be gonadotropin independent and lack follicle stimulating hormone (FSH) receptors; therefore, the first of the five suggested mechanisms seems apparently unacceptable [1 & ,4 && ,5]. However, the more advanced antral follicles, which unequivocally are gonadotropin responsive and dependent, secrete growth factors. These growth factors belong to the transforming growth factor b superfamily, such as transforming growth factor b itself, bone morphogenic proteins 2, 4, 5, 6, 7, and 15, growth differentiation factor 9, activin, and others, which in a paracrine manner cause the primordial and primary follicles to grow [5] . The gonadotoxic effect of chemotherapy brings about follicular atresia, resulting in decreased estrogen and inhibin levels, which feedback, causing an increased serum FSH, and locally, intraovarian, increased growth factors, such as bone morphogenic proteins, growth differentiation factor 9, levels, and action. Elevated levels of FSH also cause a paracrine effect, which recruits many primordial and primary follicles to enter unidirectional differentiation and apoptosis (the socalled 'burn-out theory') [5] . The chronic effect of GnRHa to decrease FSH levels may minimize further recruitment of primordial and primary follicles and their 'burn-out' [5] .
To date, over 20 studies (including six prospective RCTs), have reported on 2038 patients treated with GnRHa in parallel to chemotherapy, showing a significant decrease in premature ovarian failure (POF) rate among survivors [5] , vs. eight studies reporting on 509 patients, with negative results [5] . Patients treated with GnRHa in parallel to chemotherapy preserved their cyclic ovarian function (COF) in about 90% of cases, as compared with 40% of controls, with a pregnancy rate of 19% in the GnRHa cotreated patients [5] .
Furthermore, nine recent meta-analyses have concluded that GnRHa use may be beneficial and decrease the risk of POF in survivors [5, 6, 7 && ,8,10 12,13,14 && ]. The only prospective, randomized study with histological assessment of the follicle density and examining follicular loss following exposure to an alkylating agent, cyclophosphamide, alone or in KEY POINTS Young women exposed to gonadotoxic chemotherapy face the risk of suffering POF and infertility.
The risk of POF is correlated to age, type of chemotherapy, and cumulative dosage. The risk ranges from below 10% to over 95%.
All methods of fertility preservation should be offered to young women before gonadotoxic chemotherapy. The decision regarding which of the methods should be used is to be made by the patient after consulting with the hematologists/oncologist and reproductive endocrinologist/fertility specialist.
Despite the controversy, GnRHa has a beneficial role and may decrease the risk of POF in most female patients exposed to gonadotoxic chemotherapy. Prevention of POF is preferable to treating it, following the dictum 'An ounce of prevention is worth a pound of cure.' parallel to GnRHa cotreatment has been performed in Rhesus monkeys [15] . During the gonadotoxic exposure, the daily follicular decline was 0.12 AE 0.012% for the cyclophosphamide group compared with 0.057 AE 0.019% (P < 0.05) for the GnRHa þ cyclophosphamide group. In the cyclophosphamide group, 64.6 AE 2.8% of the total primordial follicles were lost compared with only 28.9 AE 9.1% in the GnRHa þ cyclophosphamidetreated monkeys (P < 0.05). This study clearly demonstrates that GnRHa cotreatment can protect the ovary against cyclophosphamide-induced gonadotoxicity in Rhesus monkeys [15] .
Two large and most convincing prospective . One year after chemotherapy, POF was observed in 32.3% in the chemotherapy-alone arm vs. 13.5% in the chemotherapy þ GnRHa arm (P ¼ 0.0002), with a 19% absolute reduction [95% confidence interval (CI) ¼ 8-29]. COF and premenopausal hormones levels were observed in 58% in the chemotherapyalone arm vs. 77% in the chemotherapy þ GnRHa arm (P ¼ 0.006) [5,9 && ]. Logistic regression analysis showed that GnRHa was independently associated with a higher probability of COF preservation (P ¼ 0.001) [5,9 && ]. To determine whether the administration of GnRHa in parallel to chemotherapy is a reliable strategy to preserve ovarian function on the long term and to evaluate pregnancy rate and safety concerns about the potential negative interactions between endocrine therapy and chemotherapy, the investigators evaluated the participants after a median follow-up of 7.3 years (range, 6. ]. Successful pregnancy was achieved by 12/18 women who attempted pregnancy in the chemotherapy-alone group compared with 22/25 successful pregnancies in the GnRHa arm (adjusted OR 2.45; P < 0.03). In addition, women in the GnRHa group gave birth to 18 babies vs. 12 in the standard chemotherapy group. Secondary ovarian outcomes also favored the GnRHa group, as well as better DFS and OS. The rate of DFS in the standard chemotherapy arm was 78% compared with 89% in the GnRHa arm [hazard ratio 0.49 adjusted for age, regimen, and stage, 95% CI (0.24, 0.97); P < 0.04]. In addition, the 4-year OS rate was 82% in the standard chemotherapy arm compared with 92% in the GnRHa arm [hazard ratio 0.43 adjusted for age, regimen, and stage, 95% CI (0.18, 1.0); P < 0.05].
One of the main arguments against considering the GnRHa cotreatment as an established method for fertility preservation is that preserving COF and regular menses in survivors is only a surrogate marker not equivalent to fertility, that is, pregnancies [4 && ,5] . The main weakness of studies evaluating the role of GnRHa in preserving ovarian function is the lack of data concerning the long-term maintenance of ovarian function and preservation of fertility [4 && ,5] . However, we have recently published the results of pregnancy rate in long-term survivors (up to 25 years) of chemotherapy with or without GnRHa cotreatment [4 && ]. We have compared 286 patients who received GnRHa þ chemotherapy with 188 controls (chemotherapy alone). The OR for preserving COF was 6.87 for the patients who received the GnRHa cotreatment [4 && ]. Furthermore, the total and spontaneous pregnancy rate was significantly higher for those who received the GnRHa (P < 0.006). Among the evaluable patients, more survivors in the GnRHa group resumed COF vs. patients receiving chemotherapy alone (87 vs. 49%; OR: 6.87; P < 0.0001) [4 && ]. In total, 90 patients (61%) conceived in the GnRHa group vs. 31 (42%) in the control group (P < 0.0003), resulting in 129 and 41 newborns (P < 0.01), respectively [4 && ]. Spontaneous pregnancies occurred in 80 survivors (58%) in the GnRHa group vs. 25 [14 && ] also supports the use of GnRHa in breast cancer patients stating that GnRHa therapy during chemotherapy proved effective to protect against POF and preserve fertility in young women with estrogen receptor-negative breast cancer undergoing chemotherapy. This consensus states that the GnRHa cotreatment also increased the rate of subsequent successful pregnancies and did not compromise disease outcomes [14 && ]. At the moment, there are six randomized peerreviewed studies, in addition to 15 non-RCTs and 13 meta-analyses supporting the use of GnRHa cotreatment [1 & ,4 && ,5]. However, not all the RCTs are unequivocally convincing. Another serious problem of some meta-analyses is that there is often heterogeneity of studies. Therefore, it is difficult to draw unequivocal conclusions based on meta-analyses of different studies.
In the meta-analysis by Elgindy et al. [12] , the ovarian suppression by GnRHa did not significantly increase the COF (risk ratio 1.12; P ¼ 0.07), concluding: 'it is not a reliable method for fertility preservation.' This meta-analysis has been criticized by two leading groups in fertility preservation [13, 17] . They point out that this meta-analysis assigned lower weight to the two recent, large RCTs [9 && ,16 && ] and excluded RCTs in support of GnRHa, with a possible consequent underestimate of the beneficial effect of the GnRHa cotreatment [13, 17] . They also noted that the findings in the Elgindy meta-analysis did not provide sufficient evidence of a risk-benefit analysis that would disclaim the use of GnRHa for fertility preservation. Another interesting problem associated with this meta-analysis is the inclusion of a study by Demeestere et al. [18] . This study had not found initially a difference in POF rate after 1 year; however, Demeestere et al. [18] have subsequently presented an abstract at the 3rd World Congress of the International Society for Fertility Preservation in Valencia, November 2013, whereby at 2 years follow-up of the same patients included in their previous publication declaring that: '. . .the number of patients who totally restored their ovarian function was significantly higher in the GnRHa group (P ¼ 0.049) confirming results of significantly higher AMH' levels in the GnRHa arm (1.4 ng/ml) vs. the control arm [anti-Mullerian hormone (AMH) ¼ 0.5 ng/ml], P ¼ 0.04. This supports our explanation that short follow-up may be responsible for the discrepancy between studies and lead to incorrect conclusions [1 & ,4 && ,5]. As the gold standard for fertility preservation is pregnancy, it is notable to mention that high pregnancy rates after GnRHa cotreatment vs. controls have been demonstrated in three different studies from three continents:
(1) In the study by Wong et al. [19] , in the United Kingdom, 71% of survivors treated with GnRHa and chemotherapy achieved pregnancy. (2) In the POEMS-SWOG study [16 && ], in the United States, 88% of survivors treated with GnRHa and chemotherapy achieved pregnancy.
(3) In our study [4 && ], in Israel, 61% of the survivors spontaneously conceived.
Most relevant to this equivocal and highly debatable issue, a publication [20] from one of the previous opponents of GnRHa use for fertility preservation has found that the use of GnRHa during chemotherapy has also significantly increased the probability of pregnancy (OR ¼ 12.87; P ¼ 0.001). These authors concluded: '. . .the multivariate analysis in the present study reveals that the use of GnRHa during therapy is a strong, independent, and a highly significant predictor of pregnancies.' Thus, it seems that the use of GnRHa cotreatment may preserve not only ovarian function but also fertility.
Finally, two recent international meetings of experts endorsed the GnRHa beneficial role in fertility preservation [7 && ,14 && ]. In April 2015, experts in the field of fertility preservation from several European countries were invited to Genova (Italy) to participate in a workshop on the topic of 'cancer and fertility preservation' [7 && ]. Ten controversial issues were discussed at the conference including GnRHa for fertility preservation [7 && ]. Experts were asked to present an up-to-date review of the literature published on these topics and the presentation of own unpublished data was encouraged. Ten concluding recommendations were discussed and prepared with the aim to help physicians in counseling their young patients interested in fertility preservation [7 && ]. The recommendations were graded according to the levels of evidence and grades of recommendation (according to the European Society for Medical Oncology Clinical Practice Guidelines for fertility preservation in cancer patients [7 && ,21]. The only conclusion (out of the 10) that received the highest grading I, A, according to the above classification, was the conclusion regarding GnRHa, namely: 'Ovarian suppression with the use of LHRHa during chemotherapy should be considered a reliable strategy to preserve ovarian function and fertility, at least in breast cancer patients, given the availability of new data suggesting both the safety and the efficacy of the procedure have become available (I, A)' [7 && ]. Similarly, the 2015 St. Gallen International Expert Consensus panel [14 && ] and the National Comprehensive Cancer Network guidelines (www. nccn.org) in women with hormone-receptornegative breast cancer, noted the value of a GnRHa given during chemotherapy for premenopausal women with estrogen receptor-negative disease in protecting against POF and preserving fertility.
GONADOTROPIN-RELEASING HORMONE AGONIST CONTROVERSY
An argument against GnRHa use [5] claims that: 'A clinical example for why gonadal suppression may not protect ovaries is the fact that prepubertal children receiving high-dose chemotherapy given before hematopoietic stem cell transplantation still suffer from ovarian failure.' Successful pregnancies are possible in patients undergoing prepubertal bone marrow transplantation (BMT). This is demonstrated by Remerand et al. [22] , who have described four spontaneous pregnancies and successful deliveries in a patient after prepubertal high-dose busulfan and cyclophosphamide conditioning and BMT. Similarly, a published case of repeated spontaneous pregnancies and two successful deliveries after repeated autologous BMTs and GnRHa treatment has been described, in a postpubertal lymphoma patient, suggesting that the prepubertal milieu induced by the GnRHa cotreatment might have contributed to the preserved fertility despite repeated BMT [23 & ]. In the meantime, the reported patient has experienced a third spontaneous conception and successful delivery. According to an extensive survey involving 37 362 female patients, only 0.6% of patients conceived after one autologous or allogeneic BMT [23 & ]. Thus, the estimated odds for pregnancy after two BMTs are negligible (theoretically: 0.006 Â 0.006 ¼ 0.000036) [5,23 & ]. In another study [24] conducted on 619 patients, only 3% conceived after one BMT. The theoretically estimated odds for conceiving after two stem cell transplantations are 0.03 Â 0.03 ¼ 0.0009, about 1/10 000 according to their findings [5, 24] . The administration of GnRHa before and in parallel to the gonadotoxic conditioning chemotherapy simulated the prepubertal hormonal milieu, and might have minimized the gonadotoxic effect and augmented the odds of ovulations, conceptions, and deliveries [ ]. None of the suggested avenues for fertility preservation guarantees unequivocal success in future fertility preservation. Even IVF and cryopreservation of a few embryos or unfertilized ova cannot guarantee future pregnancy. Therefore, several modalities should be combined and considered. Maximizing patients' odds for future fertility will necessitate the combination of ovarian cryopreservation, GnRHa administration, and follicular aspiration and all these modalities should be offered to each of such patients. Furthermore, GnRHa can effectively prevent the thrombocytopenia-associated menorrhagia in these patients
It has been also demonstrated that GnRHa cotreatment is beneficial not only against regular chemotherapy but also for lymphoma patients undergoing stem cell transplantation [1 & ,4 && ,5,24]. It is recommended that GnRHa cotreatment is offered in addition and not instead of IVF and cryopreservation of embryos, ova, and ovarian tissue, for fertility preservation. Furthermore, combining the various modalities for a specific patient may increase the odds of preservation of future fertility. There is no contraindication to ovarian biopsy for cryopreservation combined with GnRHa administration and follicular aspiration [1 & ,4 && ,5]. In cases where the chemotherapy has caused POF, as is frequently the case in TBI and BMT, the patient has cryopreserved ova, embryos, or primordial follicles to fall back upon. However, in cases where conventional chemotherapy regimens such as those commonly used for young lymphoma or breast cancer patients are applied, GnRHa cotreatment may preserve ovarian function and prevent POF without necessitating the use of cryopreserved ova, embryos, or ovarian tissue.
